In the present study, mucus plugs reduced in size or disappeared after treatment with anti-IL-5/IL-5Rα mAbs in 82% of patients, suggesting that these biologics directly affect the pathophysiology of ABPA. This evidence concerns the gene IL5 and allergic bronchopulmonary aspergillosis.